UBS AM’s Genomic Health, Inc. GHDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-26,843
| Closed | -$1.82M | – | 2947 |
|
|
2019
Q3 | $1.82M | Buy |
26,843
+6,351
| +31% | +$436K | ﹤0.01% | 1646 |
|
|
2019
Q2 | $1.19M | Buy |
20,492
+3,085
| +18% | +$183K | ﹤0.01% | 1817 |
|
|
2019
Q1 | $1.22M | Buy |
17,407
+4,592
| +36% | +$340K | ﹤0.01% | 1749 |
|
|
2018
Q4 | $825K | Buy |
12,815
+9,816
| +327% | +$688K | ﹤0.01% | 1826 |
|
|
2018
Q3 | $211K | Buy |
+2,999
| New | +$175K | ﹤0.01% | 2424 |
|
|
2016
Q4 | – | Sell |
-9,499
| Closed | -$275K | – | 2760 |
|
|
2016
Q3 | $275K | Hold |
9,499
| – | – | ﹤0.01% | 2312 |
|
|
2016
Q2 | $246K | Hold |
9,499
| – | – | ﹤0.01% | 2325 |
|
|
2016
Q1 | $235K | Sell |
9,499
-700
| -7% | -$19.2K | ﹤0.01% | 2354 |
|
|
2015
Q4 | $359K | Hold |
10,199
| – | – | ﹤0.01% | 2251 |
|
|
2015
Q3 | $216K | Hold |
10,199
| – | – | ﹤0.01% | 2450 |
|
|
2015
Q2 | $283K | Buy |
10,199
+600
| +6% | +$16.9K | ﹤0.01% | 2402 |
|
|
2015
Q1 | $293K | Buy |
9,599
+500
| +5% | +$15.9K | ﹤0.01% | 2277 |
|
|
2014
Q4 | $291K | Buy |
9,099
+1,300
| +17% | +$42.3K | ﹤0.01% | 2256 |
|
|
2014
Q3 | $221K | Hold |
7,799
| – | – | ﹤0.01% | 2315 |
|
|
2014
Q2 | $214K | Hold |
7,799
| – | – | ﹤0.01% | 2378 |
|
|
2014
Q1 | $205K | Hold |
7,799
| – | – | ﹤0.01% | 2411 |
|
|
2013
Q4 | $228K | Sell |
7,799
-300
| -4% | -$9.52K | ﹤0.01% | 2303 |
|
|
2013
Q3 | $248K | Hold |
8,099
| – | – | ﹤0.01% | 2205 |
|
|
2013
Q2 | $257K | Buy |
+8,099
| New | +$266K | ﹤0.01% | 2101 |
|
UBS AM's GHDX Position: Q4 2019 in Review
UBS AM sold out of Genomic Health, Inc. (GHDX) in Q4 2019, closing a stake of 26,843 shares — an estimated $1.82M sold.
UBS AM first reported a position in GHDX in Q2 2013 and held it in 19 quarters. The position peaked at $1.82M in Q3 2019. 0 funds tracked by Wall St. Rank hold GHDX as of Q4 2019.
- UBS AM reported no remaining Genomic Health, Inc. position as of Q4 2019 after selling out during the quarter.
- UBS AM sold 26,843 Genomic Health, Inc. shares in Q4 2019, an estimated $1.82M.
- UBS AM first reported a position in Genomic Health, Inc. in Q2 2013 and held it in 19 quarters.
- UBS AM's Genomic Health, Inc. position peaked at $1.82M in Q3 2019.
- 0 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q4 2019.
Based on UBS AM's 13F filing for Q4 2019, filed 14 Feb 2020.